Sensitive Cyp3a Substrates With Narrow Therapeutic Index has 2 known drug interactions based on U.S. FDA drug labeling data. Of these, 2 are contraindicated combinations that should be avoided entirely. Notable interactions include combinations with Mitapivat, Viloxazine Hydrochloride. Patients taking Sensitive Cyp3a Substrates With Narrow Therapeutic Index should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 2
- Contraindicated
- 2
Contraindicated (2)
- Sensitive Cyp3a Substrates With Narrow Therapeutic Index + Mitapivat— PYRUKYND induces CYP3A, decreasing concentrations of sensitive substrates with narrow therapeutic index. Avoid concomita…
- Sensitive Cyp3a Substrates With Narrow Therapeutic Index + Viloxazine Hydrochloride— Viloxazine is a strong CYP1A2 inhibitor that significantly increases total exposure of these substrates, increasing risk…